no problem, we,re in anticipation of rxi-109 Ph1a and Ph1b results (unblinded) , Which according to Cauwenbergh is to be announced by Q2. any time now.
Does anyone know?...................
timeframe would I think depend on the category of expediting approval;
FAST TRACK , ACCELERATED APPROVAL , or PRIORITY REVIEW.
" A process designed to facilitate the developement and expedite the review of drugs to treat diseases and fill an unmet medical need.'
" Determining whether a disease is serious is a matter of judgement but generally is based on whetherthe drug will have an impact on such factors as; survival, day to day functioning, or the likelyhood that the disease, if left untreated, will progress from a less severe one to a more serious one."
I would say that the progression of losing one's eyesight would certainly apply...IMHO
on an earlier thread, and you decline. I apologized for the curt words. You want to mix it up still. I don't recommend it but I,m game.
Please give the board your take on the current situation of ACTC, and I will follow.........
withe dmeter. meant no offense, just seems this MB a little different than what I'm used to.
My apologies to you dementr and to any one else offended.
Do not discount the possibility of a fast track approval upon further evidence of efficacy.........
Good luck all..........
No demeter, I did not compare alzheimers to AMD, neither did I compare blindness to dying as you claim I did.
My honest answer to your question;
No, you are not very bright.................
my apology demetre just don't like people putting words in my mouth. suggest you read my posts on this thread one more time........good luck
Not to be over optimistic nor attempt to outguess the next few months, but this company stands a good chance of the market handling that issue on its own.
Upon favorable results Ph1 just no telling where pps could be within the next twelve months.
My bet is they let it be for the time being, IMHO.
I did not say that blindness is deadly, but that it does certainly interfere with day to day functioning. Which is an fda guideline for unmet serious illness
You don't appear to be very bright.